基于Rulefit的预后分析,使用结构化MRI报告来选择晚期鼻癌诱导化疗的潜在受益者:双中心研究

Shuqi Li1, Weijing Zhang1, Baodan Liang1

  • 1Department of Radiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Collaborative Innovation Center for Cancer Medicine, No. 651 Dongfeng Road East, Guangzhou, Guangdong 510060, China.

概括

一个新的Rulefit模型有效地整合了用于鼻癌 (NPC) 预后的结构化MRI数据. 这种先进的模型改善了风险分层,并指导了高级NPC患者个性化诱导化疗 (IC) 决策.

相关概念视频